A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real
 world setting.
This is a non-interventional, prospective and retrospective study of participants with cHL
 and sALCL. The study will collect information on therapy and outcome of cHL and sALCL in
 real-life clinical practice.

 The study will enroll approximately 2000 participants. Based on the diagnosis of the disease,
 participants will be assigned to one of the following groups:

 -  Newly Diagnosed and RR cHL Participants

 -  Newly Diagnosed and RR sALCL Participants

 This multi-center trial will be conducted in Russia. The retrospective data will be collected
 for the participants with RR cHL or RR sALCL at the time of enrollment and for participants
 with RR cHL or RR sALCL within 3 years prior to inclusion in the study at Visit 1 (Baseline).
 The prospective data will be collected for a period of 2 years from Visit 1 (Baseline) to
 Visit 5 (Month 24, Final Visit), both for newly diagnosed participants with cHL or sALCL and
 participants with RR cHL or RR sALCL at the time of enrolment, and participants with RR cHL
 or RR sALCL within 3 years prior to inclusion in the study.
Inclusion Criteria:

 1. Male and female participants 18 years or older by the time of enrollment.

 2. Histologically confirmed diagnosis of cHL or sALCL.

 3. Newly diagnosed participants, or participants with RR cHL or RR sALCL at the time of
 enrollment, or participants with RR cHL or RR sALCL within 3 years prior to inclusion
 in the Study.

 Exclusion Criteria:

 1. Unconfirmed diagnosis of cHL or sALCL.

 2. Current, previous (within the last 3 years) or planned (for the next 2 years)
 participation in interventional clinical trials.

 3. Participation in the non-interventional study CHL-5001 "An international,
 multi-centre, non-interventional retrospective study to describe treatment pathways,
 outcomes, and resource use in participants with classical Hodgkin lymphoma
 (B-HOLISTIC)" (Sponsor is Takeda Pharmaceuticals International AG).

 4. Participants for whom the minimum study dataset was not available from their hospital
 medical records.